Skip to main content

Advertisement

Table 2 Summary of publications regarding the use of intravitreal infliximab

From: Update on intravitreal anti-tumor necrosis factor alpha therapies for ocular disorders

Publications Indication Dosing Number of cases Main results
Theodossiadis et al. [17] Neovascular AMD 2.0?mg/0.05?mL 3 BCVA improved from 20/200 to 20/40 after two monthly injections in case 1, from 20/200 to 20/70 after two bimonthly injections in case 2, and from 20/100 to 20/30 after two injections with a 3-month interval.
Giganti et al. [25] Neovascular AMD 0.5?mg/0.05?mL 2 At week 12, BCVA had declined in three patients, and electroretinography and microperimetry had a decrease in all cases.
DME 0.5?mg/0.05?mL 2
Arias et al. [26] Neovascular AMD 2.0?mg/0.05 mL 4 At 3?months after a single injection, the BCVA change was ?18, +3, +4, and ?4 letters.
Two cases developed severe intraocular inflammation.
Wu et al. [27] DME 1.0?mg/0.05?mL 15 BCVA changed from 1.49 ? 0.58 to 1.38 ? 0.56 logMAR at 3?months in the 1 mg group.
2.0?mg/0.10?mL 19 BCVA changed from 0.76 ? 0.5 to 1.03 ? 0.7 logMAR at 3?months in the 2 mg group, and 42% of cases developed severe intraocular inflammation.
Wu et al. [28] Neovascular AMD 1.0?mg/0.05?mL 8 BCVA changed from 1.04 ? 0.2 to 1.06 ? 0.5 logMAR at 3?months in the 1 mg group.
2.0?mg/0.10?mL 8 BCVA changed from 0.94 ? 0.5 at baseline to 0.85 ? 0.4 logMAR in the 2 mg infliximab group.
37.5% of eyes developed severe intraocular inflammation.
Farvardin et al. [29],[30] NIPU 1.5?mg/0.15?mL 7 BCVA changed from 1.37 ? 0.4 to 1.38 ? 0.4 logMAR at 6?months.
Vitreous haziness changed from 2.7 to 2.6 at 6?months.
Markomichelakis et al. [31] Beh?et 1.0?mg/0.05?mL 15 BCVA changed from 0.74 to 0.3 logMAR at 30?days.
Intraocular inflammation decreased through day 30.
Wu et al. [32] PCME 1.0?mg/0.10?mL 7 BCVA changed from 1.14 ? 0.6 to 0.51 ? 0.35 logMAR.
Mild intraocular inflammation was observed in one case.
  1. AMD, age-related macular degeneration; DME, diabetic macular edema; NIPU, noninfectious posterior uveitis; PCME, pseudoaphakic cystoid macular edema; BCVA, best-corrected visual acuity; logMAR, logarithm of the minimal angle of resolution.